Omitting carboplatin from neoadjuvant treatment can improve safety without compromising efficacy in patients with HER2-positive early breast cancer.

Novartis Canada is pleased to announce that Health Canada has granted a Notice of Compliance (NOC) for KISQALI® (ribociclib ...

Trastuzumab deruxtecan plus pertuzumab showed significant improvement in PFS compared with taxane chemotherapy plus ...

Inavolisib (Itovebi) is a new targeted therapy for HR+ HER2-negative metastatic breast cancer with a PIK3CA mutation.

A prognostic index can be used to identify patients with estrogen receptor (ER)-positive, HER2-negative early breast cancer who can safely forgo adjuvant chemotherapy as well as patients who require ...

AstraZeneca & Daiichi Sankyo’s Datroway gets US approval for patients with previously treated advanced EGFR-mutated NSCLC ...

Enhertu is already approved for patients with HR+, HER2-low breast cancer after endocrine therapy based on the DESTINY-Breast04 trial data, but adding the DESTINY-Breast06 data to the label ...

Cancer patients’ journeys are complex and the benefit of a drug goes well beyond survival, even in cases of incurable and/or ...

FDA grants accelerated approval to AstraZeneca's Datroway for EGFR-mutant NSCLC after prior therapies, with a 45% response ...